|
|
|
| Analysis on Prognosis and Influencing Factors in Patients with Type 1 Cardiorenal syndRome Undergoing CRRT |
| GAO Qingbao, DAI Ximing, CHEN Peng, et al |
| Sanya People's Hospital, Hainan Sanya 572000, China |
|
|
|
|
Abstract Objective: To study the continuous renal replacement therapy (CRRT) in patients with kidney syndrome (CRS) 1 core and analyzes the factors affecting prognosis. Methods: 66 patients with type 1 cardiorenal syndrome admitted to our hospital from July 2017 to September 2018 were retrospectively collected. According to the death during hospitalization, 31 cases were divided into survival group and 35 cases into death group. The clinical indicators, laboratory examination indicators, treatment parameters and left ventricular ejection fraction levels of the two groups were compared, and multivariate logistic regression analysis was made. Results: The interval between diagnosis and treatment in survival group was (3.2 +0.8) days, which was lower than that in death group (5.1 +1.2) days, with significant difference (P<0.05). The levels of alanine aminotransferase, total bilirubin and serum creatinine in survival group were lower than those in death group, and there were significant differences (all P<0.05). The left ventricular ejection fraction of survival group was (60.4 +10.3)%, which was higher than that of control group (50.7 +9.2)%. The difference was significant (P<0.05). Multivariate logistic regression analysis showed that the interval between diagnosis and treatment was a risk factor for death in CRRT patients with type 1 cardiorenal syndrome, while left ventricular ejection fraction was a protective factor. Conclusion: CRRT has a poor prognosis for type 1 CRS patients. The interval between diagnosis and treatment is an independent risk factor for death, while left ventricular ejection fraction is a protective factor.
|
|
|
|
|
|
[1] Smyth A,Ronco C,Garovic VD,et al.Preeclampsia:a cardiorenal syndrome in pregnancy[J].Curr Hypertens Rep,2017,19(2):15.
[2] Ronco C,Di Lullo L.Cardiorenal syndrome in western countries:epidemiology,diagnosis and management approaches[J].Kidney Dis(Basel),2017,2(4):151~163.
[3] 刘阳,邱光钰.重组人脑利钠肽联合连续性肾脏替代治疗心肾综合征难治性心力衰竭观察[J].中国药师,2016,19(3):532~534.
[4] 余莉晨,崔丹,毛宗福,等.武汉市医疗机构ICU中连续性肾脏替代治疗技术的应用现状[J].中华危重病急救医学,2016,28(8):732~734.
[5] 杨春霞,汪蓉,郭学珍,等.连续性肾脏替代治疗治疗不同类型心肾综合征的临床研究[J].心血管康复医学杂志,2015,24(5):565~568.
[6] 徐建国,徐敏,李钰,等.连续性肾脏替代治疗在1型心肾综合征中的应用价值[J].医学研究杂志,2015,44(4):103~106.
[7] 严文艳,邬步云,李杏,等.连续性肾脏替代治疗1型心肾综合征患者的预后及影响因素[J].肾脏病与透析肾移植杂志,2016,25(3):214~219. |
|
|
|
2019, Vol. 25 
